Sign in3 stories
The company reported cash of $11.3 million as of June 30, 2026, with runway into the first quarter of 2027, alongside clinical progress in its lead oncolytic virus program.
SEC filing
The Phase 2a study will test more frequent VCN-01 dosing in first-line metastatic pancreatic cancer patients, with initial data expected in Q3 2027.
SEC filing
At its August 3, 2026 annual meeting, Theriva Biologics shareholders approved six proposals, including an increase in shares available under its 2020 Stock Incentive Plan.
SEC filing